If approved, momelotinib will slide into GSK portfolio alongside Blenrep (belantamab mafodotin), its BCMA-targeting antibody-drug conjugate, which was approved in 2020 as a therapy for multiple ...

[17] Dr. Stephanie Ambrose, GSK Singapore Medical Director, said: "We note that myelofibrosis is a complex disease and there are significant challenges in the management of the disease ...

[5-8] (Image c/o GSK) MOMENTUM was a phase III, global, multicentre, randomised, double-blind study investigating momelotinib versus danazol in patients with myelofibrosis who were symptomatic and ...

[17] This highlights an unmet need for effective treatments for myelofibrosis patients with anaemia. [17] Dr. Stephanie Ambrose, GSK Singapore Medical Director, said: "We note that myelofibrosis is a ...